Just remember that this is the very first human trial of BIT225...

Just remember that this is the very first human trial of BIT225 for Covid patients. They are merely testing to see if they can replicate some of the results that they saw in the mouse trial and also hoping that there are no new side effects vs what has been seen in BIT225 HIV and Hep C trials. Very early days for their Covid program and the data from this trial will be used to steer future trial design.

Depending on the data there may be additional phase 2 Covid trials to narrow things down and explore the specific benefits in various cohort as has been done with HIV etc. This may include age groups. The HIV program is much more advanced and hopefully ready for phase 3 if the data supports it and there is a backer.

Specifically to your question, any future phase 3 trial design will be heavily influenced by whoever the backer of the trial is and their objectives and target market. There will be commercial considerations. Their design is then put to ethics for approval. We cannot be entirely sure how the commercial and ethical considerations will impact the age considerations for a phase 3 trial with regard to over the 60+ group. I don't think any of us here have sat on an ethics committee for drug trials so the answer to this specific question is to the best of my knowledge an unknown.